Phase II study of gemcitabine and vinorebline in patients with persistent or recurrent platinum-resistant ovarian or primary peritoneal cancer: A study of the Korean Cancer Study Group.

被引：0
|
作者：
Hong, Sook Hee
Byun, Jae Ho
Lee, Soohyeon
Kim, Hoon-Gu
Lee, Hyo Jin
Jung, Kyung Hae
Lee, Sang-Cheol
Lee, Na-Ri
Yun, Jina
Hong, Dae-Sik
Woo, In Sook
Park, Kyong Hwa
Rha, Sun Young
机构：
[1] Catholic Univ Korea, Div Oncol, Dept Internal Med, Seoul St Marys Hosp, Seoul, South Korea
[2] Catholic Univ Korea, Incheon St Marys Hosp, Inchon, South Korea
[3] Yonsei Univ, Coll Med, Dept Internal Med, Div Med Oncol, Seoul, South Korea
[4] Gyeongsang Natl Univ Hosp, Dept Internal Med, Jinju, South Korea
[5] Chungnam Natl Univ, Dept Internal Med, Coll Med, Taejon, South Korea
[6] Univ Ulsan, Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea
[7] Soonchunhyang Univ, Coll Med, Div Hematol Oncol, Dept Internal Med,Hosp Seoul, Seoul, South Korea
[8] Chonbuk Natl Univ, Sch Med, Dept Internal Med, Jeonju, South Korea
[9] Soonchunhyang Univ, Bucheon Hosp, Bucheon, South Korea
[10] Catholic Univ Korea, Yeouido St Marys Hosp, Seoul, South Korea
[11] Korea Univ, Coll Med, Div Hematol & Oncol, Dept Internal Med,Anam Hosp, Seoul 136705, South Korea
[12] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[13] Brain Korea 21 Project Med Sci, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.5568
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5568
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study
    Coleman, Robert L.
    Brady, William E.
    McMeekin, D. Scott
    Rose, Peter G.
    Soper, John T.
    Lentz, Samuel S.
    Hoffman, James S.
    Shahin, Mark S.
    GYNECOLOGIC ONCOLOGY, 2011, 122 (01) : 111 - 115
  • [22] A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study
    Monk, Bradley J.
    Kauderer, James T.
    Moxley, Katherine M.
    Bonebrake, Albert J.
    Dewdney, Summer B.
    Secord, Angeles Alvarez
    Ueland, Frederick R.
    Johnston, Carolyn M.
    Aghajanian, Carol
    GYNECOLOGIC ONCOLOGY, 2018, 151 (03) : 422 - 427
  • [23] Phase II trial of pembrolizumab with cisplatin and gemcitabine in women with recurrent platinum-resistant ovarian cancer
    Walsh, C.
    Kamrava, M.
    Rogatko, A.
    Li, A. J.
    Cass, I.
    Karlan, B. Y.
    Rimel, B. J.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 16 - 17
  • [24] Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
    Fu, Siqing
    Corr, Bradley R.
    Culm-Merdek, Kerry
    Mockbee, Colleen
    Youssoufian, Hagop
    Stagg, Robert
    Naumann, R. Wendel
    Wenham, Robert M.
    Rosengarten, Rafael D.
    Benjamin, Laura
    Hamilton, Erika Paige
    Moore, Kathleen N.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (23) : 2568 - +
  • [25] Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study
    Burger, Robert A.
    Sill, Michael W.
    Monk, Bradley J.
    Greer, Benjamin E.
    Sorosky, Joel I.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5165 - 5171
  • [26] Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study
    Keldsen, N
    Havsteen, H
    Vergote, I
    Bertelsen, K
    Jakobsen, A
    GYNECOLOGIC ONCOLOGY, 2003, 88 (02) : 118 - 122
  • [27] Preliminary results of a phase II study of gemcitabine and epirubicin in platinum-resistant or refractory advanced ovarian cancer.
    Arcuri, C
    Sorio, R
    Caffo, O
    Scalone, S
    Griso, C
    Lucenti, A
    Valdurga, F
    Frisinghelli, M
    Arisi, E
    Galligioni, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 472S - 472S
  • [28] Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer (vol 25, pg 5180, 2007)
    Cannistra
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) : 1773 - 1773
  • [29] A phase II study of irinotecan and docetaxel in patients with platinum-resistant relapsed epithelial ovarian cancer
    Matsumoto, T.
    Hiura, M.
    Oshita, T.
    Hirata, E.
    Shiroyama, Y.
    Wroblewski, J.
    Yokoyama, T.
    Nogawa, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [30] Prolonged infusion of gemcitabine in patients with platinum resistant or refractory recurrent ovarian carcinoma:: A phase II study Of GEICO (Spanish Group for investigation on ovarian cancer).
    Ojeda, B
    Gonzaléz-Martín, A
    Mellado, B
    Bover, I
    Fabregat, X
    Rubio, MJ
    Alonso, L
    Lianes, P
    Churruca, C
    Poveda, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 479S - 479S
12345